Alcon brings Balance eye drops to Latin America
This article was originally published in The Tan Sheet
Executive Summary
By the end of 2010, Alcon plans to distribute in Latin America Systane Balance Lubricant Eye Drops for consumers who have dysfunctional meibomian glands, a condition commonly linked to dry eye syndrome. The Swiss firm said Oct. 11 Systane Balance contains hydroxypropyl-guar - derived from the Guar galactomannan water-soluble polysaccharide - borate, sorbitol, propylene glycol and Alcon's LipiTech System, an emulsion technology of mineral oil and an anionic phospholipid. Alcon designed the product to restore the lipid layer and the natural tear film to allow for relief of dry eye symptoms. Tear film instability can occur when meibomian glands in eyelids do not secrete adequate amounts of lipid to seal the aqueous tears and prevent evaporation. Alcon launched the product in the U.S. in July. A 10-mL bottle of Systane Balance is available online for $12.99 and a two-bottle pack for $19.99
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.